PCSK9 Inhibitors [MoA] - N0000191730

Pharmacologic Code	N0000191730
Pharmacologic Name	PCSK9 Inhibitors
Pharmacologic Uses	PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) inhibitor
Pharmacologic Concept	Mechanisms of Action - [MoA]
Pharmacologic Concept Description	This concept refers to the mechanism of action pharmacologic action at the receptor, membrane, or tissue level. In MED-RT, molecular, subcellular, or cellular effects of drug generic ingredients, organized into a chemical function classification hierarchy, beneath the "Cellular or Molecular Interactions" concept.

The table contains 8 products whose active ingredient are classified under the same pharmacologic class PCSK9 Inhibitors [MoA].

	NDC	Proprietary Name	Non-Proprietary Name	Dosage Form	Route Name	Company Name	Status
	0024-5901	Praluent	Non-Proprietary Name: Alirocumab	Injection, Solution	Subcutaneous	Sanofi-aventis U.s. Llc	ACTIVE
	0024-5902	Praluent	Non-Proprietary Name: Alirocumab	Injection, Solution	Subcutaneous	Sanofi-aventis U.s. Llc	ACTIVE
	61755-020	Praluent	Non-Proprietary Name: Alirocumab	Injection, Solution	Subcutaneous	Regeneron Pharmaceuticals, Inc.	ACTIVE
	61755-021	Praluent	Non-Proprietary Name: Alirocumab	Injection, Solution	Subcutaneous	Regeneron Pharmaceuticals, Inc.	ACTIVE
	72511-393	Repatha	Non-Proprietary Name: Evolocumab	Injection, Solution	Subcutaneous	Amgen Usa Inc.	ACTIVE
	72511-501	Repatha	Non-Proprietary Name: Evolocumab	Injection, Solution	Subcutaneous	Amgen Usa Inc.	ACTIVE
	72511-750	Repatha	Non-Proprietary Name: Evolocumab	Injection, Solution	Subcutaneous	Amgen Usa Inc.	ACTIVE
	72511-760	Repatha	Non-Proprietary Name: Evolocumab	Injection, Solution	Subcutaneous	Amgen Usa Inc.	ACTIVE